Moderna & Merck: 5-Year Data Show Sustained RFS Benefit with Intismeran + KEYTRUDA® in High-Risk Melanoma
Moderna and Merck Report Five-Year Data Showing Sustained Improvement in Recurrence-Free Survival with Intismeran Autogene Plus KEYTRUDA® in High-Risk Stage III/IV Melanoma Patients After Complete Resection Moderna, Inc. and Merck…
ENHERTU® + Pertuzumab Validated in EU for First-Line HER2+ Metastatic Breast Cancer
ENHERTU® Plus Pertuzumab Moves Closer to EU Approval as First-Line Therapy for HER2-Positive Metastatic Breast Cancer In a significant milestone for oncology innovation, the European Medicines Agency (EMA) has officially…
Bioscience Association Manitoba Joins Premier’s Workforce Development Subcommittee
Bioscience Association Manitoba Joins Premier’s Workforce Development Subcommittee to Shape the Future of Talent and Economic Growth In a significant step toward aligning Manitoba’s economic strategy with the demands of…
Shionogi Wins Health Minister Award for Cefiderocol at Japan AMED Grand Prize
Shionogi Receives Minister of Health, Labour and Welfare Award for Cefiderocol at the 8th Japan Medical Research and Development Grand Prize Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief…
Bayer Applauds U.S. Supreme Court’s Decision to Review Durnell Case in Roundup™ Litigation
Bayer Applauds U.S. Supreme Court’s Decision to Review Durnell Case in Roundup™ Litigation The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to…
AbbVie Reports Phase 3 EPCORE® DLBCL-1 Topline Results for Epcoritamab in R/R DLBCL
AbbVie Reports Phase 3 EPCORE® DLBCL-1 Topline Results for Epcoritamab in Relapsed/Refractory DLBCL AbbVie today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific…
CAPLYTA® Shows Promise for Remission in Major Depressive Disorder
New Data Shows CAPLYTA® May Help Adults with MDD Achieve Remission Johnson & Johnson today announced a new analysis of Phase 3 data which found CAPLYTA® (lumateperone), in combination with an antidepressant,…
Opdivo® + Yervoy® Approved in Taiwan for MSI-H/dMMR Metastatic Colorectal Cancer
Opdivo® IV Infusion Approved in Taiwan in Combination with Yervoy® for Adults with Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer Ono Pharmaceutical Co., Ltd. today announced that Ono Pharma Taiwan Co.,…
Celltrion Unveils Drug Pipeline and U.S. Expansion at J.P. Morgan Conference
Celltrion Unveils Innovative Drug Pipeline and Expands U.S. Manufacturing and R&D Strategy at 44th Annual J.P. Morgan Healthcare Conference Celltrion, a leading global biopharmaceutical company, today presented key strategic priorities…
Neurocrine Shows INGREZZA® Achieves Higher VMAT2 Occupancy Than AUSTEDO XR
Neurocrine Biosciences Presents Head-to-Head Data Showing INGREZZA® (valbenazine) Capsules Achieve Higher VMAT2 Target Occupancy Than AUSTEDO XR Neurocrine Biosciences, Inc. today announced the presentation of the first head-to-head data comparing vesicular…
Johnson & Johnson Launches Mobile Simulator App to Empower Breast Augmentation Patients
Johnson & Johnson Launches Mobile Simulator App to Empower Breast Augmentation Patients Johnson & Johnson announced the U.S. launch of the Arbrea Breast Simulator Surgeon App for Mentor, a digital consultation…
TECVAYLI® Monotherapy Shows Superior Survival vs Standard Care in Early Relapsed, Heavily Pretreated Myeloma
TECVAYLI® Monotherapy Shows Superior Survival vs. Standard Care in Early Relapsed, Heavily Pretreated Multiple Myeloma Johnson & Johnson, a worldwide leader in multiple myeloma therapies, today announced positive topline results…